Healthcare Industry News: pazopanib
News Release - June 5, 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
22 US Oncology Affiliated Physicians Participate in ASCO ProceedingsHOUSTON, June 4 (HSMN NewsFeed) -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.
The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.
The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.
The research found that Therapy Arm 2 (AT-->T) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cycles-->paclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to AC-->T as a standard treatment in the community. It has more peripheral neuropathy than AC-->T; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, AP-->WP was superior to AC-->T in overall survival (OS).
In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.
-- Daniel Von Hoff, M.D., Chief Scientific Officer: The Complete Phase lb
Clinical Trial: A Method to Accelerate New Agent Development
-- Michael Teneriello, M.D., Co-Chair, Gynecologic Cancer Research
Committee, US Oncology Research: Results of a Phase II evaluation of
nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-
sensitive patients with recurrent ovarian, peritoneal, or fallopian
tube cancer
-- Patrick Timmins, III, M.D.: Preliminary results of an open-label study
to evaluate the efficacy and tolerability of aprepitant for the
prevention of chemotherapy-induced nausea and vomiting associated with
carboplatin-containing chemotherapy regimen in patients with ovarian
cancer, primary peritoneal or fallopian tube carcinoma (stage I-IV) or
papillary serous cancer of the uterus
-- Craig Reynolds, M.D., Co-Chair Lung Cancer Research Committee: An
open-label, Phase II trial of nanoparticle albumin bound paclitaxel
(nab-paclitaxel), carboplatin, and bevacizumab in first-line patients
with advanced non-squamous Non-Small Cell-Lung Cancer (NSCLC)
-- Thomas Cartwright, M.D., Co-Chair, GI Cancer Research Committee:
Results of a Phase II trial of cetuximab+XELIRI as first-line therapy
of patients with advanced and/or metastatic colorectal cancer
-- Craig Reynolds, M.D.: A randomized phase 3 trial of gemcitabine with
or without carboplatin in performance status 2 (PS2) patients (pts)
with advanced (stage IIIB with pleural effusion or IV) Non-Small-Cell
Lung Cancer (NSCLC)
-- Robert Raju, M.D.: Pemetrexed (P) in relapsed Small-Cell Lung Cancer
(SCLC): Preliminary results of a Phase II trial
-- Don Richards, M.D., Ph.D.: The impact of shortened vitamin
supplementation lead-in time before pemetrexed (P) in patients with
relapsed Small-Cell Lung Cancer (SCLC)
-- J.R. Hoverman, M.D., Medical Director of Managed Care, US Oncology:
Assessment of medication safety in the outpatient setting
-- Manuel Modiano, M.D.: A phase I study of TPI 287, a third generation
taxane, administered every 21 days in patients with advanced cancer
-- Joanne Blum, M.D., Ph.D.: Phase II study of eribulin mesylate (E7389)
halichondrin b analog in patients with refractory breast cancer
-- Alexander Spira, M.D.: Phase II study of eribulin mesylate (E7389), a
mechanistically novel inhibitor of microtubule dynamics, in patients
with advanced Non-Small Cell-Lung Cancer (NSCLC)
-- John Pippen, Jr., M.D., F.A.C.P.: "A Historical Overview of the
Treatment of Prostate Cancer and the Evolution of Bone Marrow
Transplantation"
-- Marcus Neubauer, M.D., Co-Chair: Lung Cancer Research Committee: A
clinical pathways project to promote evidence-based medicine in a large
community oncology practice
-- Domingo Perez, M.D.: Phase II trial of carboplatin, weekly paclitaxel
and biweekly bevacizumab in patients with unresectable stage IV
melanoma
-- Nicholas Robert, M.D., Co-Chair Breast Cancer Research Committee: BCIRG
006: Docetaxel and trastuzumab-based regimens improve DFS and OS over
AC-T in node positive and high risk node negative HER2 positive early
breast cancer patients: Quality of Life (QOL) at 36 months follow-up
-- Dr. Alexander Spira: Perifosine (P) an active agent in the treatment
of patients with advanced sarcoma
-- Dr. Alexander Spira: iTARGET: A Phase II Trial to Assess the Response
to Gefitinib in Epidermal Growth Factor Receptor (EGFR)-Mutated
Non-Small Cell-Lung Cancer (NSCLC) Tumors
-- Dr. Hakan Kaya: Survival outcomes for multiple myeloma over three
decades: A Surveillance, Epidemiology, and End Results (SEER) analysis
-- Dr. Hakan Kaya: Survival and secondary malignancy rates for adjuvant
radiation therapy versus observation in stage I testicular seminoma: A
Surveillance, Epidemiology, and End Results (SEER) analysis
-- Dr. Kelly Pendergrass: The Advanced Renal Cell Carcinoma Sorafenib
(ARCCS) expanded access trial: safety and efficacy in patients (pts)
with Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC)
-- Roger Lyons, M.D.: Tolerability and hematologic improvement assessed
using three alternative dosing schedules of azacitidine in patients
with myelodysplastic syndromes
-- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology
Research: pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell
Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation
Trial (RDT)
-- Guru Sonpavde, M.D.: Sunitinib malate is active and synergistic with
cisplatin against human urothelial carcinoma in a preclinical model
About US Oncology Research
The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 528 physicians actively enrolling patients, 82 research sites, and is currently involved in 65 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer- fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.
About US Oncology, Inc.
US Oncology, headquartered in Houston, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs, and participate in many of the new cancer-related clinical research studies. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.
According to the company's last quarterly earnings report, US Oncology is affiliated with 1077 physicians operating in 433 locations, including 90 radiation oncology facilities in 38 states.
Source: US Oncology
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
